Hematologic Oncology Update, Issue 3, 2014OVERVIEW OF ACTIVITY LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Williams — Advisory Committee and Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc. Dr Erba — Advisory Committee: Seattle Genetics; Consulting Agreements: Amgen Inc, Celgene Corporation, Novartis Pharmaceuticals Corporation; Contracted Research: Amgen Inc, Astellas, Celator Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Seattle Genetics; Speakers Bureau: Celgene Corporation, Incyte Corporation, Novartis Pharmaceuticals Corporation. Dr Kumar — Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi; Contracted Research: Abbott Laboratories, Celgene Corporation, Cephalon Inc, Genzyme Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi. Dr Fanale — Advisory Committee: Amgen Inc, Seattle Genetics, Spectrum Pharmaceuticals Inc; Consulting Agreement: Seattle Genetics; Contracted Research: Celgene Corporation, Genentech BioOncology, MedImmune Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Seattle Genetics and Teva Oncology. Hardware/Software Requirements: Last review date: December 2014 |